Intended for amenorrhea and abnormal uterine bleeding to manage hormonal levels and support endometrial health.
Mechanism of Action
This synthetic progestin transforms a proliferative endometrium into a secretory one. It inhibits the release of pituitary gonadotropins, which prevents follicular development and stabilizes the uterine lining.
Route of Administration
Oral
Onset Time
1–3 days
Duration
24 hours
Contraindications
Pregnancy, Thromboembolic disorders, Breast cancer, Hepatic impairment
Severe Adverse Events
Pulmonary embolism, Stroke, Bone mineral density loss — requires immediate medical attention
Common Side Effects
Nausea, Headache, Breast tenderness
Uncommon Side Effects
Weight changes, Mood changes, Insomnia
Drug Interactions
Rifampin, St. John's Wort, Alcohol, Tobacco, Phenobarbital
Pregnancy Safety Warnings
FDA Category X: Strictly contraindicated in pregnancy. Breastfeeding: Excreted in milk; monitor infant.
Age Restrictions
Clinically recognized for use in post-menarcheal females.
Information related to Medroxyprogesterone is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
